MediciNova Overview
- Founded
-
2000
- Status
-
Public
- Employees
-
11
- Stock Symbol
-
MNOV
- Investments
-
1
- Share Price
-
$2.40
- (As of Thursday Closing)
MediciNova General Information
Description
MediciNova Inc is a biopharmaceutical company. The company acquires and develops small-molecule therapeutics for the treatment of diseases with unmet medical needs with a specific focus on the U.S. market. Its products portfolio includes therapeutics such as MN-001, MN-166, MN-221 etc. The firm's current strategy is to focus its development activities on therapeutics for neurological disorders and fibrotic diseases. It has the acquisition and development of the small molecule therapeutics segments.
Contact Information
Ownership Status
Publicly Held
Financing Status
Formerly VC-backed
Primary Industry
Pharmaceuticals
Other Industries
Drug Discovery
Therapeutic Devices
Stock Exchange
NAS
Primary Office
- 4275 Executive Square
- Suite 300
- La Jolla, CA 92037
- United States
+1 (858) 000-0000
MediciNova Stock Performance
(As of Thursday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $2.40 | $2.38 | $2.09 - $4.65 | $117M | 49M | 24.6K | -$0.26 |
MediciNova Financials Summary
|
In Thousands, USD |
TTM 30-Jun-2022 | FY 2021 31-Dec-2021 | FY 2020 31-Dec-2020 | FY 2019 31-Dec-2019 |
|---|---|---|---|---|
| EV | 56,556 | 56,561 | 174,658 | 232,622 |
| Revenue | 38 | 4,038 | 0 | 0 |
| EBITDA | (13,254) | (10,249) | (14,195) | (14,053) |
| Net Income | (13,078) | (10,134) | (13,854) | (12,942) |
| Total Assets | 81,236 | 87,406 | 75,419 | 79,205 |
| Total Debt | 184 | 132 | 186 | 0 |
Public Fundamental Data provided by Morningstar, Inc.
disclaimer
MediciNova Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
MediciNova Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price |
% Owned |
|---|
MediciNova Comparisons
Description
Primary
Industry
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last Financing Details
MediciNova Inc is a biopharmaceutical company. The company acquires and develops small-molecule therapeutics for the tre
Pharmaceuticals
La Jolla, CA
11
As of 2021
00000
000000000
00000
000000
m ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat
0000 000000000
Gaithersburg, MD
00
As of 0000
000.00
000000 - 000
000.00
000000
dunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco la
0000 000000000
Cambridge, MA
000
As of 0000
00000
00000000
00000
Add Comparison
MediciNova Competitors (42)
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Altimmune | Corporate Backed or Acquired | Gaithersburg, MD | 00 | 000.00 | 000000 - 000 | 000.00 |
| 0000000 0000000000 | Formerly VC-backed | Cambridge, MA | 000 | 00000 | 00000000 | 00000 |
| 0000000 0000000000 | Formerly VC-backed | Cambridge, MA | 0000 | 00.000 | 0000 | 00.000 |
| 000000 | Formerly VC-backed | Cambridge, MA | 000 | 00000 | 00000000 | 00000 |
| 000000 00000000000 | Formerly VC-backed | Munich, Germany | 000.00 | 000000&0 | 000.00 |
MediciNova Patents
MediciNova Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| US-20210308109-A1 | Methods of reducing plasma level of macrophage migratory inhibitory factor in patients | Pending | 06-Apr-2020 | 0000000000 | |
| EP-4034090-A1 | Ibudilast oral formulations and methods of using same | Pending | 23-Sep-2019 | 0000000000 | |
| US-20210085613-A1 | Ibudilast oral formulations and methods of using same | Pending | 23-Sep-2019 | 0000000000 | |
| US-11154540-B2 | Methods of treating ophthalmic disease/disorder or injury with ibudilast | Active | 19-Oct-2018 | 0000000000 | 0 |
| US-20200121659-A1 | Methods of treating ophthalmic disease/disorder or injury with ibudilast | Granted | 19-Oct-2018 | A61K31/4355 |
MediciNova Executive Team (14)
MediciNova Board Members (12)
| Name | Representing | Role | Since |
|---|---|---|---|
| Carolyn Beaver | MediciNova | Board Member | 000 0000 |
| Hideki Nagao | MediciNova | Board Member | 000 0000 |
| Jeff Himawan Ph.D | EW Healthcare Partners | Chairman & Board Member | 000 0000 |
| Kazuko Matsuda Ph.D | MediciNova | Chief Medical Officer & Board Member | 000 0000 |
| Yuichi Iwaki MD | MediciNova | Chief Executive Officer & Board Member | 000 0000 |
MediciNova Signals
Growth Rate
0.80%
Weekly
Growth
Growth
Weekly Growth
0.80%, 93rd %
-35.5%.
530%
Size Multiple
219x
Median
Size Multiple
219x, 100th %ile
0.00x
0.95x.
413Kx
Key Data Points
Twitter Followers
5.5k
Similarweb Unique Visitors
15.0K
Majestic Referring Domains
314
MediciNova Investors
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|
MediciNova Acquisitions (1)
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| 000000 | 18-Dec-2009 | 0000000000 | 000.00 | Biotechnology | 000000 00 |